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Summary
The best approach for allogeneic haematopoietic stem cell transplantations
(alloHCT) in patients with chronic lymphocytic leukaemia (CLL) is
unknown. We therefore analysed the impact of procedure- and centre-
related factors on 5-year event-free survival (EFS) in a large retrospective
study. Data of 684 CLL patients who received a first alloHCT between 2000
and 2011 were analysed by multivariable Cox proportional hazards models
with a frailty component to investigate unexplained centre heterogeneity.
Five-year EFS of the whole cohort was 37% (95% confidence interval [CI],
34–42%). Larger numbers of CLL alloHCTs (hazard ratio [HR] 096,
P = 0002), certification of quality management (HR 07, P = 0045) and a
higher gross national income per capita (HR 04, P = 004) improved EFS.
In vivo T-cell depletion (TCD) with alemtuzumab compared to no TCD
(HR 15, P = 003), and a female donor compared to a male donor for a
male patient (HR 14, P = 002) had a negative impact on EFS, but not
non-myeloablative versus more intensive conditioning. After correcting for
patient-, procedure- and centre-characteristics, significant variation in cen-
tre outcomes persisted. In conclusion, further research on the impact of
centre and procedural characteristics is warranted. Non-myeloablative con-
ditioning appears to be the preferable approach for patients with CLL.
Keywords: chronic lymphocytic leukaemia, allogeneic stem cell trans-
plantation, risk factor analysis, centre effects, frailties.
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Despite fundamental changes in the treatment of chronic
lymphocytic leukaemia (CLL) with the introduction of the
Bruton tyrosine kinase (BTK)-inhibitors, such as ibrutinib
and acalabrutinib, phosphoinositide 3-kinase (PI3K)-inhibi-
tors, such as idelalisib, and B-cell lymphoma 2 (BCL2)-inhi-
bitors like venetoclax, some patients demonstrate only short
lasting responses (Byrd et al, 2014; Furman et al, 2014;
Roberts et al, 2015). Synergistic effects by combinations of
pathway inhibitors and antibodies are currently under inves-
tigation (Cervantes-Gomez et al, 2015; Deng et al, 2015; Thi-
jssen et al, 2015). Data on combinations or sequential
therapies of these new drugs demonstrate promising activity
but are still preliminary (Jain et al, 2015; Jones et al, 2015;
Maddocks et al, 2015; Mato et al, 2015). However, restricted
reimbursement of these expensive new drugs by national
health care systems might limit the treatment choices for
patients with CLL in many countries. For this reason, and
considering its curative potential, alloHCT will remain an
important salvage option for medically fit patients with high
risk CLL (Dreger et al, 2014; Kharfan-Dabaja et al, 2016).
For those patients in need of alloHCT, the question
remains as to which procedural choices are most promising.
With declining numbers of patients, randomized controlled
trials on procedural issues of alloHCT for patients with CLL
will hardly be feasible. It is therefore justified to exploit
registry data in order to gain insights into the most promis-
ing strategies for alloHCT. We took advantage of an exten-
sive retrospective survey of patients who were transplanted
between January 2000 and December 2011 in many different
centres across Europe, thus allowing a broad overview of
real-life practice. We set out to study the impact of condi-
tioning intensity, stem cells source and different methods of
graft-versus-host disease (GvHD) prophylaxis by T-cell
depletion (TCD) on several survival outcomes. Given that
procedural factors are closely linked to centre preferences, we
aimed at correcting the estimates for potential centre differ-
ences and at quantifying and explaining the variability in
outcomes between centres.
Methods
Approach
Data were extracted from the European Society for Blood
and Marrow Transplantation (EBMT) registry and upgraded
and updated through a Data Quality Initiative (for details see
Data S1). The two countries contributing the fewest patients
(10 in total) were excluded to restrict heterogeneity in the
sample. Data on first alloHCTs for CLL between January
2000 and December 2011 were utilized. Patients were
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excluded if they had experienced Richter transformation
prior to transplantation, or if they had received cord blood
or a graft from a mismatched related or syngeneic donor.
Definitions
Remissions were assessed according to effective guidelines of
the International Working Group for CLL (Cheson et al,
1996; Hallek et al, 2008). Purine analogue refractory disease
was defined as non-response to purine analogue-containing
chemotherapy or relapse within 6 months. Patients with re-
treatment of CLL within 24 months after purine analogue
combination chemotherapy were considered as having early
relapse.
Conditioning intensity was classified according to the
working definitions published by Bacigalupo et al (2009).
Examples for non-myeloablative conditioning (NMA) regi-
mens are 2 Gray total body irradiation (TBI) in combination
with fludarabine or cyclophosphamide in combination with
fludarabine. Examples for myeloablative conditioning (MAC)
regimens are TBI at a cumulative dose of more than 8 Gray
or doses of busulphan exceeding 8 mg/kg of the oral drug or
64 mg/kg of the i.v. formulation. Reduced-intensity (RIC)
regimens represent the intermediate category.
T-cell depleting treatments were classified in four cate-
gories, patients receiving no TCD, patients receiving anti-
thymocyte-globulin (ATG) of any brand and dose, patients
receiving alemtuzumab given within 2 weeks prior to
alloHCT and patients who received ex vivo T-cell depleted
grafts. Donor type was classified according to the definition
of Weisdorf et al (2008). Experience in alloHCT in general
and in CLL in particular was measured by counting the
number of CLL alloHCTs performed at the respective cen-
tre in the two calendar years before the patient was trans-
planted. The impact of implementation of a quality
management system was assessed by considering accredita-
tion with the Joint Accreditation Committee-International
Society for Cellular Therapy& EBMT (JACIE) from 2 calen-
dar years before it was granted (Gratwohl et al, 2011,
2014). Data were delivered by the JACIE office (Barcelona).
Gross National Income (GNI) per capita, based on purchas-
ing power parity (PPP) in the country and year in which a
patient was transplanted, was used as a proxy to macro-
economic factors (Gratwohl et al, 2015). Data available at
www.worldbank.org were used.
Statistical analysis
The outcome of primary interest was event-free survival (EFS)
up to 5 years after alloHCT as a surrogate for long-term dis-
ease control. Secondary outcomes were the cumulative inci-
dences of relapse or progression (CIR) and of non-relapse
mortality (NRM) up to 5 years after alloHCT, overall survival
(OS) in the first 100 days after alloHCT, OS after the first
relapse/progression after alloHCT and the cumulative
incidences of acute GvHD (aGvHD) and chronic GvHD
(cGvHD).
Cox multivariate regression models for (cause-specific) haz-
ards were fitted for the respective endpoints to evaluate a
potential clinical impact of risk factors on different transplant
outcomes. The focus was on procedure-related factors: donor
type, donor-patient sex match, type of conditioning, stem cell
source and TCD. Patient-related factors were included in the
models to adjust for confounding caused by differences in
patient mix between different treatment strategies and centres.
These factors have been selected on the basis of their signifi-
cance and relevance in our previous analysis of this cohort
(Schetelig et al, 2017): age, Karnofsky performance status,
prior autologous HCT, remission status at alloHCT and cyto-
genetic abnormalities (omitted for EFS). Year of alloHCT was
included as another adjustment factor. Centres were character-
ized by experience in alloHCT in general and for CLL specifi-
cally, JACIE accreditation and GNI/cap.
The Cox models were extended with a frailty component
(a random effect), shared by all patients in the same centre,
to model heterogeneity between centres not explained by
these four factors or measured differences in patient mix
(Therneau & Grambsch, 2000). These models attempt to sep-
arate true differences between centres and random fluctua-
tion. They yield (Empirical Bayes) estimates of the residual
centre effects that are reduced with respect to crude esti-
mates. These estimates were used to quantify centre variabil-
ity in outcome, expressed as a ‘centre HRs’ with respect to
the average centre.
To visualize the impact of the centre HRs on EFS proba-
bilities, we plotted predicted EFS curves of reference patients
with mean values for all covariates, including centre charac-
teristics, treated in three centres with the best, worst and an
average centre HR.
All analyses were performed in SPSS Version 23 (IBM
Statistics, IBM corporation, Armonk, NY, USA) and R 3.1.0
with the packages ‘mice’(Buuren, 2012), ‘survival’(Therneau,
2015), and ‘cmprsk’ (Gray, 2014). Further details regarding
the statistical analysis are given in Data S1.
Results
Centre and patient characteristics
Thirty centres from Germany, the Czech Republic, France,
Spain, Denmark, Switzerland, the Netherlands, Finland, Swe-
den and Norway contributed data (Table IA). In total, data
on 684 patients met the selection criteria for this analysis.
The annual number of transplantations evaluated in this
analysis increased from 22 patients in 2000 to 64 patients in
2011. The average annual number of transplants for patients
with CLL ranged from 09 (in 2000) to 42 (in 2011) per
transplant centre during this period. The average annual
numbers of overall alloHCTs ranged from 379 (in 2000) to
676 (in 2011) transplantations per centre.
Intervention-related factors impact on alloHCT for CLL
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Experience with the use of ATG was most common among
the centres (N = 23) while only 11 centres reported experience
with alemtuzumab administered for in vivo TCD and only 7
centres (of which 4 had a single patient) used ex vivo TCD.
The median age of the cohort of patients was 55 years
(range, 19–74 years) (Table IB). Most patients fulfilled crite-
ria for high-risk CLL. Only 10% of patients had never
received purine-analogues during their treatment history.
Deletion 17p had been diagnosed in 28% of patients and
overall 63% of patients met EBMT consensus indications
(Dreger et al, 2007).
Outcomes for the whole cohort and for subgroups of
patients
The median follow-up of surviving patients was 41 months
(range, 1–148 months). The probability of EFS and OS at
5 years was 37% (95% confidence interval (CI), 34–42%)
and 47% (95% CI, 43–52%), respectively. At 5 years after
alloHCT the cumulative incidence of NRM was 35% (95%
CI, 31–39%) and CIR was 28% (95% CI, 24–31%). Given
that the patients whose registry data were reviewed for the
Data Quality Initiative represent a subset of all EBMT-regis-
tered patients with CLL, we compared point estimates for
OS, EFS, NRM and CIR of both datasets. No significant
differences were found. At day 100 after alloHCT, the cumu-
lative incidence of aGvHD grades II–IV was 39% (95% CI,
35–42%) and that of grades III–IV was 15% (95% CI, 13–
18%) for the whole cohort. The cumulative incidence of
cGvHD (limited and extensive combined) at 1 year after
HCT was 52% (95% CI, 48–56%).
Outcomes by type of conditioning and TCD are shown in
Table II and Fig 1. As there were significant differences in
the risk profile at baseline among these groups, the results of
the subsequent multivariate analyses are more informative.
Results of multivariate analyses of 5-year outcomes
The main goal of the Cox regression models extended with a
frailty term was to describe the impact of procedure- and
centre-related characteristics of alloHCT for patients with
CLL on 5-year outcomes. Details on the multivariate models
for EFS, CIR and NRM are given in Table III. Among
patient and disease-related baseline risk factors, age, perfor-
mance status, a history of autologous transplantation and
remission status had a significant impact on EFS. Female
donor to male recipient alloHCTs were significantly associ-
ated with worse EFS (HR 14, 95% CI 11–18, P = 002).
After adjusting for baseline patient-related factors, donor-
related factors, year of transplantation, and measured and
Table IA. Transplant centre characteristics. (total n = 30)
Parameter Classification N (%)
Number of all alloHCTs per centre per year Median (range) 45 (0–169)
Total alloHCT volume (2000–2011) Low volume (≤450 patients) 10 (33)
median 334 patients (range 192–448)
Intermediate volume (451–700) 10 (33)
median 516 patients (range 452–589)
Large volume (>700 patients) 10 (33)
median 822 patients (range 701–1690)
Number of CLL alloHCTs per centre per year Median (range) 2 (0–19)
Total CLL alloHCT volume (2000–2011) Low volume (<20 patients) 12 (40)
median 15 patients (range 7–18)
Intermediate volume (20–34) 10 (33)
median 29 patients (range 20–31)
Large volume (≥35 patients) 8 (27)
median 52 patients (range 35–128)
JACIE accreditation No 11 (37%)
Yes 19 (63%)
Year of first JACIE accreditation (n = 19) Median (range) 2008 (2001–2011)
GNI/cap PPP per year current international $ Median (range) 32 535 (15 990–63 330)
Number (%) of centres using the respective
Conditioning Regimens*
NMA 23 (77)
RIC 28 (93)
MAC 17 (57)
Number (%) of centres using the respective
source of stem cells*
Bone marrow 22 (73)
Peripheral blood 30 (100)
Number (%) of centres using TCD* No TCD 25 (83)
In vivo TCD with ATG 23 (77)
In vivo TCD with alemtuzumab 11 (37)
Ex vivo TCD 7 (23)
*Numbers add up to more than 100% because most centres offered more than one approach
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Table IB. Patient characteristics.
Parameter* Classification N (%) (total n = 684)
Patient sex Male 503 (74)
Female 181 (26)
Age at alloHCT [years] Median (range) 55 years (19–74 years)
age <45 years [%] 79 (12)
age ≥45 to <55 years [%] 250 (37)
age ≥55 to <65 years [%] 306 (45)
age >65 years [%] 49 (7)
Karnofsky Index [%] (N = 623) 100 185 (30)
90 303 (49)
80 112 (18)
≤70 23 (4)
Interval CLL diagnosis – alloHCT <2 years 134 (20)
≥2 years to <5 years 245 (36)
≥5 years to <10 years 248 (36)
≥10 years 57 (8)
Previous autoHCT [%] Yes 72 (11)
autoHCT within 2 years prior to alloHCT 9 (1)
PA Sensitivity [%] (N = 574) PA-refractory disease 240 (42)
Relapse <24 months after PA-combination 123 (21)
PA-sensitive disease 156 (27)
PA-sensitivity not tested 55 (10)
Pre-treatment with alemtuzumab [%] (N = 547) Yes 180 (33)
No 367 (67)
Number of lines of pre-treatment (N = 622) Median (range) 3 (0–15)
0 to 2 lines of prior therapy 196 (32)
3 lines of prior therapy 143 (23)
4 lines of prior therapy 122 (20)
≥5 lines of prior therapy 161 (26)
Cytogenetic Abnormalities [%] (N = 522) Deletion 17p 144 (28)
Deletion 11q (no deletion 17p) 142 (27)
Other abnormalities 166 (32)
No abnormalities detected 70 (13)
Remission Status at alloHCT [%] (N = 645) Complete Remission 83 (13)
Partial Remission 342 (53)
Stable disease/Progressive disease 220 (34)
Conditioning Regimen [%] (N = 675) NMA 223 (33)
NMA based on 2 Gy TBI 100 (15)
NMA based on Flu/Cy 123 (18)
RIC 353 (52)
RIC based on dose-reduced Busulfan 145 (21)
RIC based on Melphalan 84 (12)
RIC based on BCNU 18 (3)
RIC based on dose-reduced Bu/Cy 20 (3)
RIC, other regimens 86 (13)
MAC 99 (15)
MAC based on TBI 64 (10)
MAC based on high-dose Busulfan 35 (5)
Donor Type [%] HLA-identical sibling 279 (41)
HLA-matched unrelated donor 322 (47)
Partially matched unrelated donor 83 (12)
Recipient-Donor sex-match [%] (N = 676) Patient male – Donor male 355 (53)
Patient male – Donor female 143 (21)
Patient female – Donor male 98 (14)
Patient female – Donor female 80 (12)
Intervention-related factors impact on alloHCT for CLL
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unmeasured centre characteristics, TCD retained a significant
impact on 5-year outcomes: according to the model, the
administration of ATG protected against NRM but entailed a
greater risk of relapse or progression. Alemtuzumab adminis-
tered for in vivo TCD was associated with a greater risk of
relapse but no significant impact on NRM. The net impact
on EFS of TCD with alemtuzumab compared to no TCD
thus was negative (HR 15, 95% CI 104–21, P = 003). Ex
vivo TCD did not show a significant negative or positive
impact on EFS, CIR or NRM.
RIC was associated with a greater risk of NRM compared
to NMA conditioning (HR 16, 95% CI 11–23, P = 0009)
and MAC had a protective impact against relapse compared
to NMA conditioning (HR 04, 95% CI 02–08, P = 0009).
Despite this, neither RIC nor MAC was associated with
improved EFS, because the reduction of the CIR was coun-
terbalanced by an increased NRM. Peripheral blood stem
cells as graft source compared to bone marrow also reduced
the CIR (HR 05, 95% CI 03–08, P = 0006) but did not
significantly impact EFS (HR 08, 95% CI 05–11, P = 02)
due to a negative impact on NRM. The same pattern applied
for human leucocyte antigen (HLA)-matched unrelated
donor versus HLA-identical sibling donor alloHCT, where a
significantly lower risk of relapse (HR 05, 95% CI 03–07,
P < 0001) was counterbalanced by a higher risk of NRM
(HR 22, 95% CI 15–32, P < 0001).
Table IB. (Continued)
Parameter* Classification N (%) (total n = 684)
Recipient-Donor CMV-Match [%] (N = 641) Patient negative – Donor negative 157 (24)
Patient negative – Donor positive 67 (10)
Patient positive – Donor negative 169 (26)
Patient positive – Donor positive 248 (39)
Source of stem cells [%] Bone marrow 48 (7)
Peripheral blood 636 (93)
TCD [%] (N = 676) No TCD 354 (52)
In vivo TCD with ATG 204 (30)
In vivo TCD with alemtuzumab 74 (11)
Ex vivo TCD 44 (7)
Year of allogeneic HCT 2000–2001 64 (9)
2002–2003 102 (15)
2004–2005 114 (17)
2006–2007 123 (18)
2008–2009 147 (21)
2010–2011 134 (20)
GNI/cap PPP per year [current international $] Low GNI (15 990–30 000) 222 (32)
Intermediate GNI (30 000–40 000) 307 (45)
High GNI (40 000–63 330) 155 (23)
alloHCT, allogeneic haematopoietic cell transplantation; ATG: anti-thymocyte globulin; autoHCT, autologous haematopoietic cell transplantation;
CLL, chronic lymphocytic leukaemia; CMV, cytomegalovirus; Cy, cyclophosphamide; Flu, fludarabine; GNI/cap PPP, Gross National Income per
capita based on purchasing power parity; HCT, haematopoietic cell transplantation; HLA, human leucocyte antigen; JACIE, Joint Accreditation
Committee-International Society for Cellular Therapy and European Society for Blood and Marrow Transplantation; MAC, myeloablative condi-
tioning; N, number; NMA, non-myeloablative; PA, purine-analogue; RIC, reduced-intensity conditioning; TBI, total body irradiation; TCD, T-cell
depletion.
*The number of patients with available information is given in brackets if this deviates from the total number.
Table II. Time-to-event outcomes in patients with chronic lympho-
cytic leukaemia at 5 years after allogeneic haematopoietic cell trans-
plantation by Conditioning intensity and TCD.
Risk factor
Event-free
survival
Cumulative
incidence of
relapse/
progression
Non-relapse
mortality
% (95% CI) % (95% CI) % (95% CI)
Conditioning intensity
Non-
myeloablative
43% (36–51%) 30% (23–37%) 27% (20–33%)
Reduced
intensity
32% (26–38%) 28% (23–33%) 40% (35–46%)
Myeloablative 46% (36–58%) 23% (13–32%) 32% (22–42%)
TCD
None 42% (36–48%) 23% (18–28%) 36% (30–41%)
ATG 37% (30–45%) 31% (23–38%) 33% (26–40%)
Alemtuzumab 14% (8–27%) 46% (34–58%) 40% (28–52%)
Ex vivo TCD 50% (36–69%) 26% (12–41%) 23% (10–36%)
The P-value for event-free survival is derived from the log-rank test;
it compares the event-free survival of the groups during the first
5 years after alloHCT. The P-values for cumulative incidence of
relapse/progression and non-relapse mortality are derived from
Gray’s test; it compares the cumulative incidence curves of the
groups during the first 5 years after alloHCT.
ATG, anti-thymocyte globulin; CI, Confidence Interval; TCD, T-cell
depletion.
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In order to study differences in transplant centre outcome,
the model also included variables capturing disease-specific
experience, provision of quality management and the eco-
nomic situation. We found a trend for less relapse/progres-
sion (HR 096 per additional transplantation, 95% CI 09–
1002, P = 006) and a significant lower risk of NRM (HR
096, 95% CI 093–099, P = 0005) in centres with higher
numbers of alloHCTs for patients with CLL. Quality man-
agement was associated with a significantly lower risk of
relapse/progression (HR 05, 95% CI 03–08, P = 0003).
Higher GNI per capita showed a strong positive association
with better EFS (HR 04, 95% CI 02–096, P = 004). How-
ever, even when including these variables to the regression
model, residual variation between centres in 5-year EFS due
to unmeasured centre differences was still present (test for
variance of the centre effects: P = 002). The hazard ratios
for 5-year EFS ranged between 06 (transplant centre with
best outcome) and 12 (worst outcome) in the dataset.
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Fig 1. Event-free survival, cumulative incidence of relapse/progression and non-relapse mortality by type of conditioning (A–C) and T-cell deple-
tion (D–F). Panels A, D: Kaplan–Meier plots for event-free survival from haematopoietic cell transplantation. Panels B, E: Cumulative incidence
plots for relapse/progression. Panes C, F: Cumulative incidence plots for non-relapse mortality. EFS, event-free survival; HCT, haematopoietic cell
transplantation.
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Table III. Risk factors for event-free survival, non-relapse mortality and relapse/progression within the first 5 years after alloHCTin patients with
CLL. Models with factors describing centre characteristics.
Risk factors
Event-free survival up to
5 years
Risk of relapse/progression up
to 5 years
Risk of non-relapse mortality
up to 5 years
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age by decade 12 101–136 003 09 07–11 04 14 12–18 <0001
Karnofsky Index 002 03 004
90–100% 1 1 1
80% 15 11–19 0009 14 09–22 01 15 11–22 002
≤70% 17 09–32 007 13 05–36 05 19 09–39 008
Prior autologous HCT 0003 <000 03
No 1 1 1 1
Yes 17 12–24 24 15–38 12 08–19
Remission Status at alloHCT 001 <0001 04
Complete Remission 1 1 1
Partial Remission 13 09–19 01 35 16–77 0002 08 05–12 03
SD/PD 17 12–26 0007 49 22–112 <0001 09 06–15 08
Cytogenetic abnormalities – – – 03 06
Deletion 17p 1 1
Deletion 11q (no del 17p) 09 05–15 07 09 06–13 06
Other/no abnormalities 07 04–11 01 08 06–12 04
Donor Type 06 0002 <0001
HLA-identical Sibling 1 1 1
Matched UD 11 08–15 05 05 03–07 <0001 22 15–32 <0001
Partially matched UD 12 08–18 03 06 03–10 006 23 15–38 <0001
Donor-Patient Sex Match 001 009 003
Male into Male 1 1 1
Female into Male 14 11–18 002 11 07–17 06 16 12–23 0005
Male into Female 09 07–13 06 06 04–11 01 12 08–18 04
Female into Female 08 05–11 01 06 03–11 008 09 06–15 07
Year of Transplantation 11 104–118 0002 12 11–13 <0001 10 09–11 09
Conditioning Intensity 03 003 004
Non-myeloablative 1 1 1
Reduced intensity 11 09–15 03 07 05–11 01 16 11–23 0009
Myeloablative 09 06–13 05 04 02–08 0009 13 08–22 03
Stem cell source
Bone marrow 1 1 1
PBSC 08 05–11 02 05 03–08 0006 11 06–19 07
TCD 009 0003 006
None 1 1 1
Anti-Thymocyte-Globulin 09 07–13 06 17 1003–27 0048 06 04–09 0007
Alemtuzumab 15 104–21 003 27 16–45 <0001 08 05–14 05
Ex vivo TCD 09 05–16 08 13 05–33 05 08 04–16 05
alloHCT Volume of TC
per alloHCT in 2 prior years 100 100–100 02 100 100–101 02 100 100–100 07
CLL alloHCT Volume of TC
per alloHCT in 2 prior years 096 093–098 0002 096 09–100 006 096 093–099 0005
JACIE accreditation 0045 0003 09
No 1 1 1
Yes 07 05–099 05 03–08 098 07–14
Logarithm of GNI per cap PPP/1000 04 02–096 004 04 01–15 02 05 02–11 008
Coefficients and their Confidence Intervals and P-values have been estimated in (cause-specific) multivariate Cox proportional hazards models
after a Multiple Imputation procedure.
alloHCT, allogeneic HCT, haematopoietic cell transplantation; ATG, anti-thymocyte globulin; CI, confidence interval; GNI per cap PPP, Gross
National Income per capita based on purchasing power parity in current international $; HLA, human leucocyte antigen; HR, hazard ratio;
JACIE, Joint Accreditation Committee- International Society for Cellular Therapy and European Society for Blood and Marrow Transplantation;
PBSC, peripheral blood stem cells; PD, progressive disease; SD, stable disease; TC, transplant centre; TCD, T-cell depletion; UD, unrelated donor.
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Figure 2 shows the corresponding range of model-based EFS
curves (indicating the average centre and the centres with
best and worst outcome, adjusting for known factors) for a
reference patient. Figure 3 illustrates how the Cox model
with a frailty component shrinks the estimates of the centre
effects with respect to crude estimates.
Mortality within the first 100 days and after relapse/
progression
We also investigated the impact of procedure- and centre-
related risk factors on mortality in the first 100 days after
alloHCT. Day 100 mortality was not significantly different
among transplant centres and none of the centre-related fac-
tors had a significant impact on outcome. After adjusting for
patient-related risk factors, patients who received NMA con-
ditioning had the lowest day 100 mortality. The HR compar-
ing RIC versus NMA was 22 (95% CI 11–46, P = 003)
and the HR comparing MA versus NMA was 23 (95% CI
09–56, P = 008).
Data of 170 patients who experienced relapse or progres-
sion after alloHCT were available (characteristics of these
patients are provided in Table SI). Two-year OS after
relapse/progression from first alloHCT was 42% (95% CI
31–57%) after NMA conditioning, 41% (95% CI, 31–54%)
after RIC, and 30% (95% CI, 14–62%) after MA condition-
ing for first alloHCT, respectively (Figure S1A). Two-year OS
of patients with ex vivo TCD for first alloHCT was 57%
(95% CI, 35–94%), with alemtuzumab 45% (95% CI, 29–
68%), with ATG 39% (95% CI, 27–56%) and without either
type of TCD 36% (95% CI, 25–50%), respectively
(Figure S1B). No significant centre variability or impact of
centre-related factors was found for mortality after relapse/
progression.
Discussion
Chronic lymphocytic leukaemia represents a rare indication
for alloHCT. During the study period the median annual
number of alloHCTs per centre for patients with CLL was
only 2, ranging from 0 to 19 transplantations. For such rare
transplant indications it is difficult to set up local disease-
specific guidelines for alloHCT. Even for study alliances it is
almost impossible to conduct prospective clinical trials on
alloHCT for patients with CLL in order to evaluate procedu-
ral factors. This setting justifies well-conducted international
registry-based retrospective studies. However, centres often
have preferences on how to deliver alloHCT in certain dis-
eases and thus the challenge arises to distinguish between the
impact of variations in procedures, and of known and
unmeasured centre characteristics on different outcomes. The
issue of potential centre effects has only been addressed in a
minority of published studies, and more advanced statistical
methodology has rarely been applied for this specific purpose
(Andersen et al, 1999; Loberiza et al, 2003; Katsahian et al,
2006; Logan et al, 2008). Frailty models, as utilized for this
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Fig 2. Impact of centre-effects on event-free survival. The impact of
unmeasured characteristics of centres on EFS is shown in a model-
based plot after adjusting for known patient-, procedure- and mea-
sured centre-related factors. Outcomes are shown for three reference
patients who share the same values for all predictors in the model
(the mean values in the dataset) who would be transplanted in cen-
tres with the highest, lowest and average frailty (centre HR) in the
dataset. Unmeasured centre effects may represent patient selection,
external factors or centre-specific factors that have an influence on
outcome not accounted for in the model. EFS, event-free survival;
HCT, haematopoietic cell transplantation; HR, hazard ratio.
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Fig 3. Model-based shrinkage of centre effects. The figure illustrates
the impact of unmeasured centre characteristics on 5-year event-free
survival for the 30 centres in the sample. Triangles indicate crude
estimates of centre effects, calculated as the ratio of the observed and
expected number of events in a centre. The expected number of
events is based on measured patient and centre characteristics. Dots
indicate the estimates of residual centre effects (HRs) taken from the
Cox models with a frailty component as described in the methods
section. These estimates take into account measured patient and cen-
tre characteristics. The centre effects (frailties) derived from this
model are always smaller compared to the crude estimates, thereby
accounting for chance fluctuations between centres. Points to the
right of the vertical broken line indicate centres with a higher than
average incidence of relapse and death and points on the left of the
line indicate centres with a lower than average incidence of relapse
and death. A frailty of one indicates no deviation from the average
outcome.
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study, allow for separation of observed centre effects into
explained variation by case mix and centre characteristics,
unexplained differences between centre outcomes and ran-
dom fluctuations (Glidden & Vittinghoff, 2004). These mod-
els have been investigated and their use recommended in
statistical literature, however, they have been very rarely used
for studies in the medical context.
We present data of a large cohort of patients who were
well characterized with respect to their treatment history and
disease biology as reported by the transplant centres that par-
ticipated in a data quality initiative to upgrade and update
baseline and outcome data. Owing to the retrospective nat-
ure, some important limitations also had to be accepted:
detailed information on monitoring of minimal residual dis-
ease (MRD) and MRD-triggered interventions after alloHCT
and data on comorbidity was not available. Further, the con-
tributing centres are not a random sample of all transplant
centres reporting to the EBMT. The fact that these centres
contributed to the data quality initiative could indicate a spe-
cial commitment for patients with CLL. Moreover, distribu-
tion of risk factors and treatment choices might also differ
somewhat from that of all transplanted CLL patients. The
results of this study may therefore not display the full range
of variation in outcome.
In this study we exemplarily show the impact of disease-
specific expertise on transplant outcomes in patients with a
rare indication for alloHCT. More experience, measured by
the number of transplants in this indication in the two pre-
ceding years, had a positive impact on EFS (HR 096 per
alloHCT, P = 0002) and was associated with a lower risk of
NRM (HR 096 per alloHCT, P = 0005). In contrast to
Gratwohl et al (2015), who found an impact of the total
number of alloHCTs at a centre in a large study of 37 542
alloHCTs, the total alloHCT volume of the transplant centre
did not show a significant impact on EFS, CIR or NRM in
our data. But, like others before, we could show that accredi-
tation with JACIE and larger GNI per capita based on PPP
had a beneficial impact on EFS (Gratwohl et al, 2011, 2014,
2015). Measured and unmeasured centre characteristics did
not have a significant impact on 100-day mortality and sur-
vival after relapse.
When accounting for measured patient-, disease-, proce-
dure- and centre-related characteristics, substantial variation
of centre outcome in terms of EFS remained. The magnitude
of unexplained centre variation is displayed by the centre-
specific frailties, ranging from 06 to 12 for the centres in
the dataset, equivalent to a HR of 2 for the centre with worst
outcome compared to the top centre, even after adjustment
for all measured covariates. The systematic shrinkage of cen-
tre effects protects against over-interpretation of extreme out-
comes of small centres. In turn, some centre effects may be
underestimated and the real differences may be even larger.
These unexplained centre effects probably represent a mix-
ture of differences which could apply to the location of the
transplant centre (e.g. environmental influences or buildings
and structures of the hospital determining the risk of infec-
tions), unmeasured characteristics of the patient population
transplanted at this centre (e.g. socio-economic status, mari-
tal status, comorbidity), selection criteria which were not
reported (e.g. based on insurance status or local contraindi-
cations against alloHCT) and factors determining the success
of the transplant procedure which might differ between cen-
tres (e.g. team expertise, the schema for MRD monitoring,
the strategy for immune-modulation, the quality of the fol-
low-up programme). When considering this long list of
potential factors it appears unlikely that one single factor
causes all unexplained variation in outcomes, but also that
all information on potential risk factors will ever be col-
lected.
How can the results then be used? The range of the frail-
ties indicates the potential size of a bias when preferentially
single-centre data from transplant centres with better out-
comes are published. Our results might therefore be used as
note of caution when such studies are interpreted.
A major result of our study is that, even after adjustment
for these centre-related factors, some procedure-related fac-
tors retained their impact on EFS. With respect to TCD, the
data suggest that in vivo TCD with alemtuzumab has a nega-
tive impact on EFS, which was mainly caused by an
increased incidence of relapse. The British Society of Blood
and Marrow Transplantation (BSBMT) reported results on
41 consecutive patients who received alemtuzumab-based
RIC alloHCT for CLL and found a probability of EFS at
2 years after alloHCT of 45% (95% CI, 27–62%) (Delgado
et al, 2006). In our larger cohort of 74 patients who received
alemtuzumab-based conditioning we found a 2-year proba-
bility of EFS of only 29% (95% CI, 20–43%). Multiple rea-
sons may account for this difference, among them specific
expertise in using alemtuzumab in the BSBMT group. Dosing
of alemtuzumab with the goal of in vivo TCD is especially
challenging in patients with CLL due to the variable amount
of target antigen presented by residual CLL cells (Hale et al,
2004). As a consequence, the depth of in vivo TCD can vary
among patients, which may encompass differences in trans-
plant outcomes. Moreover, the distribution of risk factors
might have been different between the British and the EBMT
patients.
With respect to conditioning intensity, our results suggest
that dose intensity does translate into better control of CLL.
However, this comes at the price of higher NRM. This pat-
tern has been shown before for patients with CLL (Dreger
et al, 2005). Given the full pipeline of new drugs for CLL, a
rational decision would be to accept less risk of NRM but
higher risk of relapse and therefore to opt for the least toxic
approach for conditioning. Exemplarily, a growing body of
clinical data suggests that the BTK-inhibitor ibrutinib is safe
and efficacious for the treatment of relapse after alloHCT
(Link et al, 2016; Michallet et al, 2016; Ryan et al, 2016).
In conclusion, the observation that disease-specific centre
experience and JACIE accreditation have a beneficial impact
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on transplant outcomes indicates the possibility that in rare
transplant indications, disease-specific transplant programmes
which aim at standardization of the preparative phase, the
transplant procedure, disease monitoring and immune-mod-
ulation after alloHCT could improve the outcome at
transplant centres.
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Key Points
• Event-free survival after allogeneic stem cell transplantation
for patients with CLL varies significantly between centres.
Differences in patient mix, procedure-related factors and
centre characteristics explain part of the observed differ-
ences.
• Non-myeloablative conditioning did not have a negative
impact on EFS and exposed patients to a lower risk of
non-relapse mortality. For patients with CLL, the least
toxic approach for conditioning should be preferred.
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Fig S1. Title: Death after relapse by previous treatment
approach (conditioning intensity & TCD). The left panel (A)
shows death after relapse by conditioning intensity for first
transplantation. The right panel (B) shows death after relapse
by T-cell depletion for first alloHCT. In these plots time zero
is the day of first relapse/progression after first alloHCT.
Table SI. Characteristics of patients with relapse/progres-
sion after first alloHCT.
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